Harm reduction in anabolic androgenic steroid use

Conditions: middelenmisbruik, afhankelijkheid
androgen abuse
use of anabolic steroids
10019654
10038716

Registration Number: NL-OMON52267

Lead Sponsor: Elisabeth-Tweesteden ziekenhuis

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: Not specified

Target Recruitment: 100

Inclusion Criteria

• Men of at least 18 years old.
• The subjects intents to start an androgen cycle within 2 weeks after
enrollment.
• The planned cycle has an average weekly dose >250 mg and duration >6 weeks.

Exclusion Criteria

• The use of AAS in the 3 months prior to enrollment (except for TRT <250
mg/week).
• When in the last 6 months:
1) A new somatic or psychiatric illness was diagnosed.
2) A medication for chronic illness was started or changed.
3) A (non-traumatic) hospital admission occured (or psychiatric ward
admission).

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>• The effect of a harm reduction strategy on the duration of exposure to AAS by<br /><br>amateur athletes in a 12 month study period.<br /><br>• The effect of a one-time online consultation about diet and training regimens<br /><br>on the duration of exposure to AAS in a 12 month study period.<br /><br>• The extent to which providing a harm reduction intervention leads to a<br /><br>different amount of new users of AAS.<br /><br>• The prevalence of obstructive sleep apnea syndrome during AAS use.<br /><br>• The prevalence of non-alcoholic fatty liver disease during AAS use.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>• The effect of a harm reduction strategy on the duration of growth hormone use<br /><br>and the number of times post-cycle therapy is employed in a 12 month study<br /><br>period.<br /><br>• The extent to which the different user typologies predict the effectiveness<br /><br>of the harm reduction strategy..<br /><br>• The incidence of serious adverse events during or after AAS use. </p><br>